Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04282824 · ClinicalTrials.gov registry record · Early Phase 1

Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer

A Early Phase 1 study of Prostate Carcinoma, sponsored by Jonsson Comprehensive Cancer Center.

Completed
Registry status
Early Phase 1
Development phase
14
Enrollment target
1
Study location

NCT04282824 is a Early Phase 1 study of Prostate Carcinoma that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 14 participants, below the 1,502-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04282824, a Early Phase 1 study of Prostate Carcinoma, has completed, sponsored by Jonsson Comprehensive Cancer Center.

COMPLETED
Registry status
Early Phase 1
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies the impact of monosodium glutamate (MSG) on 68GA-PSMA-11 PET/CT in decreasing the salivary glands uptake in patients with prostate cancer. Prostate specific membrane antigen (PSMA) is a molecule that is overexpressed by the prostate cancer cells. 68GA-PSMA-11 is an imaging radioactive drug that can target this molecule in tissues for imaging and therapy of prostate cancer. Food substances, such as monosodium glutamate, may reduce salivary gland uptake of 68GA-PSMA-11. Ultimately, giving MSG may reduce potential harm and injury to the salivary glands in patients with prostate cancer treated with PSMA-targeted molecular radiotherapy.

Conditions Studied

Prostate Carcinoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Positron Emission Tomography
  • DRUG Gallium Ga 68-labeled PSMA-11
  • DIETARY_SUPPLEMENT Monosodium Glutamate

Study Locations (1)

California

  • UCLA / Jonsson Comprehensive Cancer Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2019-06-05
Est. Completion 2020-05-06
Phase Early Phase 1

Sponsor

Jonsson Comprehensive Cancer Center

321 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04282824

The ClinicalTrials.gov registry entry for NCT04282824 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,502-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (99% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT04282824 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04282824 about?

NCT04282824 is a clinical study titled "Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer". This phase I trial studies the impact of monosodium glutamate (MSG) on 68GA-PSMA-11 PET/CT in decreasing the salivary glands uptake in patients with prostate cancer. Prostate specific membrane antigen (PSMA) is a molecule that is overexpressed by the prostate cancer cells. 68GA-PSMA-11 is an imaging...

What is the current status of trial NCT04282824?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2019-06-05. Estimated completion is 2020-05-06.

What conditions does trial NCT04282824 study?

This clinical trial studies the following conditions: Prostate Carcinoma.

What interventions are being tested in trial NCT04282824?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Gallium Ga 68-labeled PSMA-11 (DRUG), Monosodium Glutamate (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT04282824?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04282824 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.